Stay updated with breaking news from Breakthrough Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") and Seagen Inc. (Nasdaq: SGEN) today announced that on November...
Merck’s investigational 21-valent pneumococcal conjugate vaccine, V116, achieved positive immune responses in pneumococcal vaccine-naïve adults.
The FDA approved Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. Nirogacestat is a new molecular entity and the first drug to be approved for the treatment of patients with desmoid tumors, a subtype of soft tissue sarcomas.
French drug major Sanofi (SNYNF, SNY) announced Monday positive results of Dupixent (dupilumab) Phase 3 trial in chronic obstructive pulmonary disease or COPD. In the second Dupixent investigational Phase 3 trial - NOTUS, Dupixent significantly reduced COPD exacerbations.
NOTUS trial met its primary endpoint with overwhelming efficacy, showing Dupixent significantly reduced exacerbations by 34% compared to placebo in patients with moderate-to-severe COPD with evidence...